Idaho

Overview

Idaho is one of the most restrictive cannabis-policy states in the United States. As of 2026, Idaho has no medical-cannabis program and prohibits adult-use cannabis statewide. Idaho also prohibits any cannabis-derived product containing more than 0.3% THC under Idaho Code Title 37 Chapter 27 (the Uniform Controlled Substances Act).

In 2021, the Idaho legislature enacted Senate Joint Resolution 101, a proposed constitutional amendment that would have entrenched cannabis prohibition in the Idaho Constitution; the resolution did not advance to the ballot. Subsequent ballot-initiative attempts to authorize medical cannabis (including the 2020 "Idaho Medical Marijuana Act" initiative) have failed to qualify.

Medical status

Idaho operates no medical-cannabis program. There is no patient registry, no dispensary licensing framework, and no statutory qualifying-condition list. Idaho residents seeking medical cannabis must obtain it from another state's program. Possession in Idaho remains criminal regardless of out-of-state medical authorization.

Recreational status

Recreational cannabis is illegal statewide. Penalties under Idaho Code §37-2732(c):

• Possession of 3 ounces or less: misdemeanor. Up to 1 year jail and $1,000 fine.
• Possession over 3 ounces: felony. Up to 5 years and $10,000.
• Manufacture or delivery: felony with penalties scaling by quantity, up to a 15-year, $25,000 ceiling for substantial quantities.
• Trafficking thresholds: mandatory minimum sentences begin at 1 pound.

Idaho law-enforcement agencies maintain active enforcement at state borders adjacent to Washington, Oregon, Montana, and Nevada (all legalized adult-use neighbors). I-84, I-90, US-95, and US-20 corridors receive concentrated enforcement attention.

CBD authorization

Idaho permits possession of CBD products containing 0.3% THC or less that are derived from compliant hemp. The state has narrow medical-research authorizations under prior legislation but has not implemented a patient-access framework.

Patients and caregivers

Idaho recognizes no patient or caregiver category. The state has no qualifying-condition list, no patient registry, no licensed dispensaries, and no caregiver designation framework. Pediatric epilepsy cases that elsewhere qualify for low-THC oil access have no statutory pathway in Idaho. Families in this position have historically relocated or sourced product from adjacent states at federal-law risk.

Reciprocity and visiting patients

Idaho does not extend reciprocity to any out-of-state medical program. Visiting patients carrying medical cards from Washington, Oregon, Montana, Nevada, Utah, or any other state receive zero legal protection. Possession remains a misdemeanor or felony depending on quantity. Idaho prosecutors have not adopted patient-status as a mitigating factor in published charging decisions.

Employment and workplace

Idaho is an at-will employment state with no statutory protection for cannabis use. Employers may terminate workers for any positive THC test result. This applies regardless of how the test was triggered (pre-employment, random, post-accident, reasonable suspicion). Workers' compensation claims may be denied for accidents where post-incident testing returns positive for THC, even at low or historical-use levels.

Public-employee positions and any federal-contractor role follow federal drug-free workplace rules. Healthcare workers, commercial drivers, law-enforcement officers, and education employees face additional licensing-board exposure beyond employer discipline.

Hemp-derived intoxicants

Idaho enforces a stricter hemp standard than the federal Farm Bill. Idaho Code §37-2701 historically defined any THC content above zero as marijuana, creating practical zero-tolerance for hemp-derived products. Subsequent statutory adjustments aligned Idaho with the federal 0.3% THC threshold for industrial-hemp products specifically, but enforcement remains tighter than in neighboring states. Idaho retailers face state-level scrutiny for delta-8 THC, delta-10 THC, THC-O, and HHC products, and the Idaho Office of Drug Policy has issued multiple advisories treating these compounds as controlled substances.

Recent legislative history

Comprehensive medical-cannabis reform bills have been introduced in Idaho without enactment for over a decade. Ballot-initiative efforts faced compounded obstacles after the 2021 Senate Joint Resolution 101 vote (which sought to entrench prohibition constitutionally) and after the legislature tightened ballot-initiative signature-distribution requirements in 2021 (Senate Bill 1110, partially struck down by the Idaho Supreme Court).

The April 2026 federal Schedule III rescheduling order produced no Idaho legislative response. The Idaho Office of Drug Policy issued a public statement reaffirming that state-level cannabis law was unaffected by federal scheduling changes.